HC Wainwright Reiterates Buy Rating for Connect Biopharma (NASDAQ:CNTB)

Connect Biopharma (NASDAQ:CNTB – Get a Free Report)His stock was reiterated by investment analysts at HC Wainwright in a research report issued on Friday, Benzinga reports. They currently have a $8.00 price objective on the stock.

Connect Biopharma price performance

Shares of NASDAQ:CNTB opened at $1.25 on Friday. The stock’s 50-day simple moving average is $1.22, and its two-hundred-day simple moving average is $1.42. Connect Biopharma has a 52-week low of $0.53 and a 52-week high of $2.84.

Institutional Trading of Connect Biopharma

A hedge fund recently increased its stake in Connect Biopharma shares. Keudell Morrison Wealth Management boosted its holdings in shares of Connect Biopharma Holdings Limited (NASDAQ:CNTB – Free Report) by 63.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 32,200 shares of the company’s stock after acquiring an additional 12,500 shares during the period. Keudell Morrison Wealth Management owned about 0.06% of Connect Biopharma worth $49,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 58.72% of the company’s shares.

Link Biopharma company profile

(Get a free report)

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, is engaged in the development of therapies for the treatment of T-cell-driven inflammatory diseases. The company builds a series of small molecules and antibodies using T-cell functional assays to detect and discover potent candidates of products against validated immune targets.

Recommended articles

Get news and reviews for Connect Biopharma Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Connect Biopharma and related companies with MarketBeat.com’s FREE daily email newsletter.